23ME-00610

· 23andMe, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for 23ME-00610, covering 2024-11-15 to 2024-11-15. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies [Phase 1, Phase 2]